Literature DB >> 11118388

Concerns regarding the Centers for Disease Control's published guidelines for pelvic inflammatory disease.

D L Hemsel1, W J Ledger, M Martens, G R Monif, N G Osborne, J L Thomason.   

Abstract

The International-Infectious Disease Society for Obstetrics and Gynecology-USA (I-IDSOG-USA) has concerns about the most recently published Centers for Disease Control and Prevention (CDC) guidelines for pelvic inflammatory disease (PID). I-IDSOG-USA advocates the following changes when the guidelines are revised. We recommend the use of the term "upper genital tract infection" (UGTI), followed by the designation of the etiologic agent, instead of the currently employed term, "pelvic inflammatory disease," or PID. In diagnoses, there should be greater emphasis on signs and symptoms related to subclinical or occult UGTI. Therapeutic recommendation for the treatment of UGTI should be documented for various stages of this diverse disease entity. There should be greater emphasis on hospitalization for infected nulligravida teenagers. This permits monitoring of antibiotic treatment and provides a site for medical educational efforts to teach this medically underserved segment of our society how to protect their future fertility, their health, and their lives.

Entities:  

Mesh:

Year:  2000        PMID: 11118388     DOI: 10.1086/317529

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management.

Authors:  Richard L Sweet
Journal:  Curr Infect Dis Rep       Date:  2012-02-02       Impact factor: 3.725

2.  Adverse adolescent reproductive health outcomes after pelvic inflammatory disease.

Authors:  Maria Trent; Catherine L Haggerty; Jacky M Jennings; Sunghee Lee; Debra C Bass; Roberta Ness
Journal:  Arch Pediatr Adolesc Med       Date:  2011-01

Review 3.  Treatment of acute pelvic inflammatory disease.

Authors:  Richard L Sweet
Journal:  Infect Dis Obstet Gynecol       Date:  2011-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.